Noninvasive respiratory support outside the intensive care unit for acute respiratory failure related to coronavirus-19 disease: a systematic review and meta-analysis.
COVID-19
/ mortality
Continuous Positive Airway Pressure
Hospital Mortality
Humans
Intensive Care Units
Intubation
/ statistics & numerical data
Noninvasive Ventilation
Observational Studies as Topic
Randomized Controlled Trials as Topic
Respiration, Artificial
Respiratory Distress Syndrome
/ therapy
COVID-19
Intra-hospital mortality
Noninvasive ventilation
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
30 07 2021
30 07 2021
Historique:
received:
29
03
2021
accepted:
21
07
2021
entrez:
31
7
2021
pubmed:
1
8
2021
medline:
10
8
2021
Statut:
epublish
Résumé
Noninvasive respiratory support (NIRS) has been diffusely employed outside the intensive care unit (ICU) to face the high request of ventilatory support due to the massive influx of patients with acute respiratory failure (ARF) caused by coronavirus-19 disease (COVID-19). We sought to summarize the evidence on clinically relevant outcomes in COVID-19 patients supported by NIV outside the ICU. We searched PUBMED®, EMBASE®, and the Cochrane Controlled Clinical trials register, along with medRxiv and bioRxiv repositories for pre-prints, for observational studies and randomized controlled trials, from inception to the end of February 2021. Two authors independently selected the investigations according to the following criteria: (1) observational study or randomized clinical trials enrolling ≥ 50 hospitalized patients undergoing NIRS outside the ICU, (2) laboratory-confirmed COVID-19, and (3) at least the intra-hospital mortality reported. Preferred Reporting Items for Systematic reviews and Meta-analysis guidelines were followed. Data extraction was independently performed by two authors to assess: investigation features, demographics and clinical characteristics, treatments employed, NIRS regulations, and clinical outcomes. Methodological index for nonrandomized studies tool was applied to determine the quality of the enrolled studies. The primary outcome was to assess the overall intra-hospital mortality of patients under NIRS outside the ICU. The secondary outcomes included the proportions intra-hospital mortalities of patients who underwent invasive mechanical ventilation following NIRS failure and of those with 'do-not-intubate' (DNI) orders. Seventeen investigations (14 peer-reviewed and 3 pre-prints) were included with a low risk of bias and a high heterogeneity, for a total of 3377 patients. The overall intra-hospital mortality of patients receiving NIRS outside the ICU was 36% [30-41%]. 26% [21-30%] of the patients failed NIRS and required intubation, with an intra-hospital mortality rising to 45% [36-54%]. 23% [15-32%] of the patients received DNI orders with an intra-hospital mortality of 72% [65-78%]. Oxygenation on admission was the main source of between-study heterogeneity. During COVID-19 outbreak, delivering NIRS outside the ICU revealed as a feasible strategy to cope with the massive demand of ventilatory assistance. PROSPERO, https://www.crd.york.ac.uk/prospero/ , CRD42020224788, December 11, 2020.
Sections du résumé
BACKGROUND
Noninvasive respiratory support (NIRS) has been diffusely employed outside the intensive care unit (ICU) to face the high request of ventilatory support due to the massive influx of patients with acute respiratory failure (ARF) caused by coronavirus-19 disease (COVID-19). We sought to summarize the evidence on clinically relevant outcomes in COVID-19 patients supported by NIV outside the ICU.
METHODS
We searched PUBMED®, EMBASE®, and the Cochrane Controlled Clinical trials register, along with medRxiv and bioRxiv repositories for pre-prints, for observational studies and randomized controlled trials, from inception to the end of February 2021. Two authors independently selected the investigations according to the following criteria: (1) observational study or randomized clinical trials enrolling ≥ 50 hospitalized patients undergoing NIRS outside the ICU, (2) laboratory-confirmed COVID-19, and (3) at least the intra-hospital mortality reported. Preferred Reporting Items for Systematic reviews and Meta-analysis guidelines were followed. Data extraction was independently performed by two authors to assess: investigation features, demographics and clinical characteristics, treatments employed, NIRS regulations, and clinical outcomes. Methodological index for nonrandomized studies tool was applied to determine the quality of the enrolled studies. The primary outcome was to assess the overall intra-hospital mortality of patients under NIRS outside the ICU. The secondary outcomes included the proportions intra-hospital mortalities of patients who underwent invasive mechanical ventilation following NIRS failure and of those with 'do-not-intubate' (DNI) orders.
RESULTS
Seventeen investigations (14 peer-reviewed and 3 pre-prints) were included with a low risk of bias and a high heterogeneity, for a total of 3377 patients. The overall intra-hospital mortality of patients receiving NIRS outside the ICU was 36% [30-41%]. 26% [21-30%] of the patients failed NIRS and required intubation, with an intra-hospital mortality rising to 45% [36-54%]. 23% [15-32%] of the patients received DNI orders with an intra-hospital mortality of 72% [65-78%]. Oxygenation on admission was the main source of between-study heterogeneity.
CONCLUSIONS
During COVID-19 outbreak, delivering NIRS outside the ICU revealed as a feasible strategy to cope with the massive demand of ventilatory assistance.
REGISTRATION
PROSPERO, https://www.crd.york.ac.uk/prospero/ , CRD42020224788, December 11, 2020.
Identifiants
pubmed: 34330320
doi: 10.1186/s13054-021-03697-0
pii: 10.1186/s13054-021-03697-0
pmc: PMC8324455
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
268Informations de copyright
© 2021. The Author(s).
Références
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Sarcoidosis Vasc Diffuse Lung Dis. 2021;38(2):e2021017
pubmed: 34316257
Multidiscip Respir Med. 2020 Nov 06;15(1):704
pubmed: 33282282
ERJ Open Res. 2021 Jan 25;7(1):
pubmed: 33527074
Ann Am Thorac Soc. 2021 Jun;18(6):1020-1026
pubmed: 33395553
Clin Epidemiol. 2020 Dec 30;12:1421-1431
pubmed: 33408529
Semin Respir Crit Care Med. 2014 Aug;35(4):492-500
pubmed: 25111645
Eur Respir J. 2017 Aug 31;50(2):
pubmed: 28860265
Crit Care. 2020 Jul 2;24(1):389
pubmed: 32616077
Eur Respir J. 2021 Apr 15;57(4):
pubmed: 33692120
EClinicalMedicine. 2020 Jun 18;24:100419
pubmed: 32766538
Influenza Other Respir Viruses. 2019 Jul;13(4):382-390
pubmed: 30884185
Intensive Care Med. 2020 May;46(5):854-887
pubmed: 32222812
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
JAMA Intern Med. 2020 Oct 1;180(10):1345-1355
pubmed: 32667669
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Crit Care. 2020 Sep 29;24(1):589
pubmed: 32993751
JAMA. 2021 May 4;325(17):1731-1743
pubmed: 33764378
ANZ J Surg. 2003 Sep;73(9):712-6
pubmed: 12956787
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Crit Care. 2013 Feb;28(1):14-21
pubmed: 22981534
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Crit Care Med. 2018 Aug;46(8):1209-1216
pubmed: 29498939
Prehosp Disaster Med. 2020 Aug;35(4):431-433
pubmed: 32423513
Intern Emerg Med. 2021 Aug;16(5):1183-1190
pubmed: 33222116
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
Respirology. 2020 Dec;25(12):1316-1319
pubmed: 33140491
Chest. 2004 Sep;126(3):845-50
pubmed: 15364765
Crit Care. 2021 Feb 24;25(1):80
pubmed: 33627169
Cancer. 2016 Jun 1;122(11):1749-56
pubmed: 26992109
Crit Care Med. 2019 Oct;47(10):1396-1401
pubmed: 31305497
Am J Respir Crit Care Med. 2017 Jan 1;195(1):67-77
pubmed: 27753501
Eur Respir J. 2020 Oct 15;56(4):
pubmed: 32747395
Eur Respir J. 2021 Feb 17;57(2):
pubmed: 33033151
Intensive Care Med. 2020 Jan;46(1):36-45
pubmed: 31659387
Eur Respir J. 2020 May 21;55(5):
pubmed: 32265307
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Chest. 2014 Sep;146(3):573-582
pubmed: 24522751
Am J Respir Crit Care Med. 2017 Feb 15;195(4):438-442
pubmed: 27626833
N Engl J Med. 2015 Jun 4;372(23):2185-96
pubmed: 25981908
Eur Respir Rev. 2014 Dec;23(134):427-38
pubmed: 25445941
Am J Emerg Med. 2021 Jan;39:154-157
pubmed: 33067061
Minerva Med. 2020 Sep 30;:
pubmed: 32996727
Eur Respir J. 2020 Nov 5;56(5):
pubmed: 32747398
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Intern Emerg Med. 2021 Jun;16(4):1051-1060
pubmed: 33175297